Related Experiment Video
Updated: Apr 25, 2026

An Acute Retinal Model for Evaluating Blood Retinal Barrier Breach and Potential Drugs for Treatment
Published on: September 13, 2016
[Pathopshysiological mechanisms in macular edema].
Intravitreal pharmacotherapy is now standard for diabetic macular edema, surpassing laser treatments. Emerging intravitreal devices offer new therapeutic options for this condition.
Area of Science:
- Ophthalmology
- Endocrinology
- Pharmacology
Context:
- Diabetic macular edema (DME) treatment has rapidly evolved.
- Shift from laser monotherapy to intravitreal pharmacotherapy is standard practice.
- Intravitreal injections show continuous development and positive outcomes.
Purpose:
- To review current and future treatments for diabetic macular edema.
- To evaluate the efficacy of intravitreal therapies compared to laser treatments.
Summary:
- Intravitreal pharmacotherapy, including injections and devices, is a viable and superior alternative to laser monotherapy for DME.
- Recent clinical studies confirm the effectiveness of intravitreal treatments.
- The article discusses advancements and future directions in DME management.
Impact:
- Highlights the significant progress in managing diabetic macular edema.
- Provides insights into the benefits of intravitreal treatments for patients with DME.
- Informs clinical practice and future research in retinal vascular diseases.
More Related Videos
10:24Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
12:28Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
Published on: March 12, 2022
Related Concept Videos
Cerebral Edema ll: Pathophysiology
Cerebral Edema l: Introduction
Cytotoxic Edema: Pathophysiology
Pulmonary Edema II: Pathophysiology
Diabetic Retinopathy
Heart Failure II: Pathophysiology